COMPANY PROFILE

BioGenCell

Explore full profile

Uses stem cells from the patient’s own blood to treat microvascular diseases and designs cellular therapies

Hod Hasharon, IsraelFounded 2008Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About BioGenCell

BioGenCell is a biotechnology company specializing in personalized cell therapy for vascular diseases. The company leverages a unique combination of immunology and stem cell technology to develop treatments that can be administered within a day in any clinic. BioGenCell primarily serves patients suffering from life-threatening vascular conditions, offering a groundbreaking technology for the automated production of personalized stem cell therapies. Operating in the biotechnology and pharmaceutical market, BioGenCell's business model focuses on providing safe, effective, and accessible treatments. The company generates revenue through the development and sale of its proprietary therapies, targeting a wide range of degenerative vascular diseases. BioGenCell's mission is to shape the future of healthcare by making personalized stem cell therapy available on demand, ensuring high standards of safety and efficacy. Keywords: personalized therapy, stem cells, vascular diseases, immunology, biotechnology, automated production, rapid treatment, degenerative diseases, healthcare innovation, patient-friendly.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2008
Headquarters: Hod Hasharon, Israel
Employees: 14
Open positions: None listed
Dealroom signal: 68.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Personal Health, Diabetes, Intellectual Property, Biotechnology, Oncology, Cardiology and cardiovascular, Stem Cells, Degenerative Diseases, Regenerative Medicine, Immune System
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	May 2022	$16M	$64M	Marius Nacht	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

BioGenCell website traffic

Latest recorded traffic for BioGenCell is 1.5K monthly website visits, up 417.2% over the last three months. BioGenCell's team declined 6.7% over the past year.

Latest monthly visits1.5K 3-month web change+417.2% 1-year team growth-6.7%

Monthly website visitsJun 2015–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational	16	$14M	$26M
OROrgenesisDeveloping and manufacturing cell-therapy solutions	Tel Aviv-Yafo, Israel	Operational
MLMedGenome LabsA genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome	Foster City, United States	Operational
OPOmthera PharmaceuticalsDevelops therapies for patients with elevated triglyceride levels and increased risk of cardiovascular disease	Princeton, United States	Acquired
MAMapmygenomeA molecular diagnostics company	Hyderabad, India	Operational
SPSynta PharmaceuticalsInnovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients	Lexington, United States	Acquired
ACAcceraBiotechnology company engaged in the discovery and development of therapeutic drugs for neurodegenerative diseases	Denver, United States	Operational
HUHumaProvides a digital health platform used for predictive care and research	London, United Kingdom	Operational